Treatment of Breast Cancer-related Lymphedema With Stem Cells and Fat Grafting

NCT ID: NCT03776721

Last Updated: 2021-06-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-12-18

Study Completion Date

2021-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Breast cancer-related lymphedema is one of the most common and feared consequences of breast cancer treatment. Currently, lymphedema is primarily addressed conservatively with compression garments. Regenerative medicine may provide a new treatment option for lymphedema. This Phase 3 trial will examine the efficacy, effectiveness and safety of freshly isolated adipose-derived stromal cells administered in conjunction with a fat grafting procedure to the affected axillary region.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lymphedema

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors
All patients undergo the same liposuction procedure. During general anesthesia, patients are randomized to either fat grafting or sham grafting with saline injection to the axilla. After stem cell suspension, patients receive either stem cell or saline injection depending on randomization using masked syringes.

Participants are blinded, care providers postoperatively are blinded, primary investigator is blinded and all outcome assessors are blinded. The surgeon performing the liposuction and the stem-cell staff are unblinded.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active treatment

Group Type EXPERIMENTAL

Liposuction

Intervention Type PROCEDURE

Liposuction is performed on the abdomen or thighs.

Fat graft

Intervention Type PROCEDURE

30mL harvested lipoaspirate is injected at the affected axillary site.

Stem cell injection

Intervention Type BIOLOGICAL

4mL stem cell suspension injected at the affected axillary site.

Placebo treatment

Group Type PLACEBO_COMPARATOR

Liposuction

Intervention Type PROCEDURE

Liposuction is performed on the abdomen or thighs.

Sham graf (Saline injection)

Intervention Type PROCEDURE

30mL saline is injected at the affected axillary site.

Saline injection

Intervention Type PROCEDURE

4mL saline injected at the affected axillary site.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Liposuction

Liposuction is performed on the abdomen or thighs.

Intervention Type PROCEDURE

Fat graft

30mL harvested lipoaspirate is injected at the affected axillary site.

Intervention Type PROCEDURE

Sham graf (Saline injection)

30mL saline is injected at the affected axillary site.

Intervention Type PROCEDURE

Stem cell injection

4mL stem cell suspension injected at the affected axillary site.

Intervention Type BIOLOGICAL

Saline injection

4mL saline injected at the affected axillary site.

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

lipotransfer

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Unilateral arm lymphedema secondary to breast cancer treatment including lymph node dissection.
* Cancer free for at least 1 year
* The patient understands the nature and purpose of this study and the study procedures and has signed informed consent.
* The opposite upper extremity is healthy (no lymphedema).
* ASA score of 1 or 2.
* The patient is able to read, understand, and complete Danish questionnaires.
* Pitting lymphedema ISL grade 1 or 2.
* A minimum circumference difference of 2cm or a minimum volume difference of 200mL.

Exclusion Criteria

* Pregnant or lactating.
* Bilateral lymphedema
* Current or previous malignancies other than breast cancer.
* Insulin-dependent diabetes.
* Diagnosed with any form of psychotic disorder, which may impact study participation.
* Not ceased smoking during treatment.
* Active implantables (e.g. pacemaker or neurostimulator)
* Unrealistic treatment expectations.
* Known hepatitis, HIV or syphilis infection.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Odense University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mads Gustaf Jørgensen

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jens A Sørensen, MD, PhD

Role: STUDY_CHAIR

Department of Plastic Surgery, Odense University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Plastic and Reconstructive Surgery

Odense, , Denmark

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark

References

Explore related publications, articles, or registry entries linked to this study.

Jorgensen MG, Jensen CH, Hermann AP, Andersen DC, Toyserkani NM, Sheikh SP, Sorensen JA. No Clinical Efficacy of Adipose-Derived Regenerative Cells and Lipotransfer in Breast Cancer-Related Lymphedema: A Double-Blind Placebo-Controlled Phase II Trial. Plast Reconstr Surg. 2024 Dec 1;154(6):1172-1182. doi: 10.1097/PRS.0000000000011343. Epub 2024 Feb 7.

Reference Type DERIVED
PMID: 39591365 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

S-20180117

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Topical Tacrolimus for Breast Cancer-related Lymphedema
NCT06306274 ENROLLING_BY_INVITATION PHASE2/PHASE3
Lymphovenous Anastomosis for Breast Cancer Lymphedema
NCT06302361 ACTIVE_NOT_RECRUITING NA